Literature DB >> 10680594

Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells.

D Kuwahara1, K Tsutsumi, T Kobayashi, T Hasunuma, K Nishioka.   

Abstract

The aim of this study was to understand the molecular requirements for cisplatin-induced apoptosis in human head and neck squamous cell carcinoma (HNSCC) cell death. Cisplatin induced apoptosis in HNSCC cell lines, HSC-2, HSC-3 and HSC-4 in a dose-dependent manner. However, cisplatin did not induce the expression of Fas-ligand mRNA or upregulation of Fas protein. By caspase activation assays, cisplatin induced Caspase-3 (Casp-3), -8 and -9 activation. In all three lines tested, the use of a specific inhibitor of Casp-9 almost completely blocked cisplatin-induced apoptosis, while the use of Casp-3 and -8 inhibitors resulted in a partial blockade of cisplatin-induced apoptosis. Our results strongly suggest that Casp-9-dependent apoptosis plays an important role in cisplatin-induced HNSCC apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680594     DOI: 10.1016/s0304-3835(99)00315-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand.

Authors:  Raj K Koiri; Surendra K Trigun; Lallan Mishra; Kiran Pandey; Deobrat Dixit; Santosh K Dubey
Journal:  Invest New Drugs       Date:  2008-11-29       Impact factor: 3.850

2.  Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats.

Authors:  Naomi Lomeli; Kaijun Di; Jennifer Czerniawski; John F Guzowski; Daniela A Bota
Journal:  Free Radic Biol Med       Date:  2016-11-28       Impact factor: 7.376

3.  A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis.

Authors:  Soumya Chatterjee; Ilaria Biondi; Paul J Dyson; Arindam Bhattacharyya
Journal:  J Biol Inorg Chem       Date:  2011-03-25       Impact factor: 3.358

4.  Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.

Authors:  Dan-Dan Yu; Chun-Ting Wang; Hua-Shan Shi; Zhi-Yong Li; Li Pan; Qing-Zhong Yuan; Fei Leng; Yuan Wen; Xiang Chen; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-05-12

5.  Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Authors:  Pachiyappan Kamarajan; Nian-Kang Sun; Chuck C-K Chao
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

6.  Gap junction enhancer increases efficacy of cisplatin to attenuate mammary tumor growth.

Authors:  Stephanie N Shishido; Thu A Nguyen
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

7.  Effect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosis.

Authors:  Guang-quan Li; Xing-gui Chen; Xing-ping Wu; Jing-dun Xie; Yong-ju Liang; Xiao-qin Zhao; Wei-qiang Chen; Li-wu Fu
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.

Authors:  Ryan K Van Laar
Journal:  BMC Med Genomics       Date:  2012-07-02       Impact factor: 3.063

9.  Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.

Authors:  Chen-Hsi Hsieh; Mei-Ling Hou; Meng-Hsuan Chiang; Hung-Chi Tai; Hui-Ju Tien; Li-Ying Wang; Tung-Hu Tsai; Yu-Jen Chen
Journal:  J Transl Med       Date:  2013-09-26       Impact factor: 5.531

10.  Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics.

Authors:  Sarah Schoch; Sabine Gajewski; Jana Rothfuß; Andrea Hartwig; Beate Köberle
Journal:  Int J Mol Sci       Date:  2020-09-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.